YJ9069

YJ9069 is a proteolysis-targeting chimera (PROTAC) designed to induce the selective degradation of Cyclin K. Developed by researchers at the University of Nebraska Medical Center, YJ9069 is being investigated for the treatment of pancreatic ductal adenocarcinoma (PDAC). Cyclin K is a master regulator of tumor growth and immune response in pancreatic cancer, and its expression is often elevated in pancreatic tumors, correlating with poor survival. By depleting Cyclin K, YJ9069 restricts tumor cell proliferation, induces apoptosis, and activates systemic anti-tumor immunity. In preclinical models, YJ9069 has demonstrated significant anti-tumor growth effects in immunocompetent mice and has shown synergy when combined with chemotherapy regimens such as gemcitabine and paclitaxel (GemTaxol).